AU2014205642B2 - Pyrido- or pyrrolo-fused pyrimidine derivatives as autotaxin inhibitors for treating pain - Google Patents

Pyrido- or pyrrolo-fused pyrimidine derivatives as autotaxin inhibitors for treating pain Download PDF

Info

Publication number
AU2014205642B2
AU2014205642B2 AU2014205642A AU2014205642A AU2014205642B2 AU 2014205642 B2 AU2014205642 B2 AU 2014205642B2 AU 2014205642 A AU2014205642 A AU 2014205642A AU 2014205642 A AU2014205642 A AU 2014205642A AU 2014205642 B2 AU2014205642 B2 AU 2014205642B2
Authority
AU
Australia
Prior art keywords
dihydro
equiv
mmoles
ylamino
inden
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014205642A
Other languages
English (en)
Other versions
AU2014205642A1 (en
Inventor
Thomas James Beauchamp
Yen Dao
Spencer Brian Jones
Bryan Hurst Norman
Lance Allen Pfeifer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2014205642A1 publication Critical patent/AU2014205642A1/en
Application granted granted Critical
Publication of AU2014205642B2 publication Critical patent/AU2014205642B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
AU2014205642A 2013-01-11 2014-01-07 Pyrido- or pyrrolo-fused pyrimidine derivatives as autotaxin inhibitors for treating pain Ceased AU2014205642B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361751363P 2013-01-11 2013-01-11
US61/751,363 2013-01-11
US201361777201P 2013-03-12 2013-03-12
US61/777,201 2013-03-12
PCT/US2014/010400 WO2014110000A1 (en) 2013-01-11 2014-01-07 Pyrido- or pyrrolo-fused pyrimidine derivatives as autotaxin inhibitors for treating pain

Publications (2)

Publication Number Publication Date
AU2014205642A1 AU2014205642A1 (en) 2015-07-02
AU2014205642B2 true AU2014205642B2 (en) 2016-02-25

Family

ID=50031555

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014205642A Ceased AU2014205642B2 (en) 2013-01-11 2014-01-07 Pyrido- or pyrrolo-fused pyrimidine derivatives as autotaxin inhibitors for treating pain

Country Status (13)

Country Link
US (1) US8969555B2 (enExample)
EP (1) EP2943494B1 (enExample)
JP (1) JP6285461B2 (enExample)
KR (1) KR101757997B1 (enExample)
CN (1) CN104903327B (enExample)
AU (1) AU2014205642B2 (enExample)
BR (1) BR112015015812A2 (enExample)
CA (1) CA2893253C (enExample)
EA (1) EA025106B1 (enExample)
ES (1) ES2636248T3 (enExample)
MX (1) MX2015008971A (enExample)
TW (1) TWI499591B (enExample)
WO (1) WO2014110000A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201500356A (zh) * 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物
PE20160654A1 (es) 2013-11-22 2016-07-15 Pharmakea Inc Compuestos de inhibidor de autotaxina
US9051320B1 (en) 2014-08-18 2015-06-09 Pharmakea, Inc. Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
CN116059203A (zh) 2015-05-27 2023-05-05 赛博治疗有限责任公司 自分泌运动因子抑制剂及其用途
US10118904B2 (en) 2015-06-05 2018-11-06 Vertex Pharmaceuticals Incorporated Triazoles for the treatment of Demyelinating Diseases
WO2018106643A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Heterocyclic azoles for the treatment of demyelinating diseases
WO2018106646A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en) 2016-12-06 2018-06-14 Vertex Pharmaceuticals Incorporated Pyrazoles for the treatment of demyelinating diseases
KR101798840B1 (ko) 2017-05-17 2017-11-17 주식회사 레고켐 바이오사이언스 신규 오토탁신 저해 화합물 및 이를 함유하는 약제학적 조성물
US10961242B2 (en) 2017-05-17 2021-03-30 Legochem Biosciences, Inc. Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same
JP7274767B2 (ja) * 2018-05-24 2023-05-17 ▲広▼州市恒▲諾▼康医▲薬▼科技有限公司 芳香族複素環式化合物及びその医薬組成物
US20220081400A1 (en) * 2018-07-16 2022-03-17 The Scripps Research Institute Opioid haptens, conjugates, vaccines, and methods of generating antibodies
KR102629358B1 (ko) * 2019-02-01 2024-01-24 우한 휴먼웰 이노베이티브 드러그 리서치 앤드 디벨롭먼트 센터 리미티드 컴퍼니 피롤로피리미딘 유도체 및 그의 용도
CA3149062A1 (en) * 2019-09-06 2021-03-11 Xuejun Zhang Pyrimidine compound and preparation method therefor
CA3150700A1 (en) * 2019-09-17 2021-03-25 Renato T. Skerlj IMIDAZOLE SUBSTITUTE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
WO2021088957A1 (zh) * 2019-11-07 2021-05-14 广州市恒诺康医药科技有限公司 芳杂环化合物、其药物组合物及其应用
US20230069174A1 (en) * 2019-12-11 2023-03-02 Sichuan Haisco Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic autotaxin inhibitor, and composition containing same and use thereof
CN113943296B (zh) * 2020-07-16 2025-07-04 武汉人福创新药物研发中心有限公司 吡咯并嘧啶衍生物及其应用
CN113943295B (zh) * 2020-07-16 2025-08-12 武汉人福创新药物研发中心有限公司 吡咯并嘧啶类化合物及其用途
TWI894325B (zh) * 2020-07-28 2025-08-21 大陸商武漢人福創新藥物研發中心有限公司 含氮雜環化合物的鹽及其鹽的固體形式、藥物組合物和用途
CN113999235B (zh) * 2020-07-28 2025-06-10 武汉人福创新药物研发中心有限公司 含氮杂环化合物的固体形式及其药物组合物和用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SV2002000205A (es) 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
DE102004020908A1 (de) 2004-04-28 2005-11-17 Grünenthal GmbH Substituierte 5,6,7,8,-Tetrahydro-pyrido[4,3-d]pyrimidin-2-yl- und 5,6,7,8,-Tetrahydro-chinazolin-2-yl-Verbindungen
JP5198256B2 (ja) * 2005-05-04 2013-05-15 エボテク エージー 縮合複素環式化合物、並びにそれらの組成物及び使用
US8530650B2 (en) * 2008-12-01 2013-09-10 Merck Patent Gmbh 2, 5-diamino-substituted pyrido [4, 3-D] pyrimidines as autotaxin inhibitors against cancer
WO2012009258A2 (en) * 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
EP2606031B1 (en) * 2010-08-20 2017-09-27 Amira Pharmaceuticals, Inc. Autotaxin inhibitors and uses thereof
WO2013054185A1 (en) * 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
EP3243815B1 (en) * 2011-10-28 2019-07-10 Inhibitaxin Limited Pyridazine derivatives useful in therapy
TW201520219A (zh) * 2013-03-12 2015-06-01 Lilly Co Eli 咪唑並吡啶化合物
TW201500356A (zh) * 2013-04-12 2015-01-01 Lilly Co Eli 二氫吡啶并嘧啶化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085167A1 (en) * 2010-12-22 2012-06-28 Merz Pharma Gmbh & Co. Kgaa Metabotropic glutamate receptor modulators

Also Published As

Publication number Publication date
CA2893253C (en) 2017-11-28
KR101757997B1 (ko) 2017-07-13
AU2014205642A1 (en) 2015-07-02
JP6285461B2 (ja) 2018-02-28
ES2636248T3 (es) 2017-10-05
BR112015015812A2 (pt) 2017-07-11
TWI499591B (zh) 2015-09-11
EA025106B1 (ru) 2016-11-30
US8969555B2 (en) 2015-03-03
TW201437209A (zh) 2014-10-01
EP2943494A1 (en) 2015-11-18
CN104903327B (zh) 2016-09-07
EA201591098A1 (ru) 2015-11-30
CN104903327A (zh) 2015-09-09
EP2943494B1 (en) 2017-02-22
JP2016505010A (ja) 2016-02-18
CA2893253A1 (en) 2014-07-17
US20140200231A1 (en) 2014-07-17
KR20150092761A (ko) 2015-08-13
WO2014110000A1 (en) 2014-07-17
MX2015008971A (es) 2015-09-28

Similar Documents

Publication Publication Date Title
AU2014205642A1 (en) Pyrido- or pyrrolo-fused pyrimidine derivatives as autotaxin inhibitors for treating pain
AU2014251250B2 (en) Dihydropyrido pyrimidine compounds as autotaxin inhibitors
CA2900956C (en) Imidazo pyridine compounds
WO2008049105A2 (en) Sulfamoyl-containing derivatives and uses thereof
ES2911428T3 (es) Inhibidores de STAT3
EP3045453A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
AU662384B2 (en) Heterocyclic sulfonamide derivatives as antagonists of paf and angiotensin II
EP2188276B1 (en) Substituted hydantoins
Cai et al. Design, synthesis and biological activity of tetrazole-bearing uric acid transporter 1 inhibitors
EP0549352A2 (en) Tricyclic compounds as angiotensin II antagonists
TW202333677A (zh) 蛋白質激酶C θ抑制劑
CN120965698A (zh) 一种（1,1,1-三氯-2）氨基甲酸酯类衍生物及其制备方法和应用
JPWO2000076980A1 (ja) 新規な含窒素複素環誘導体又はその塩
HK1245767A1 (en) Nrf2 regulators

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired